Pharvaris N.V.
PHVS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001830487
In the last 90 days, Pharvaris N.V. insiders filed 0 open-market purchases and 20 sales; 125 institutions reported holding it in 13F filings for Q2 2026, worth $2.23B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q2 2024
Institutional positions in Pharvaris N.V. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 36
- +1 vs. Q1 2024
- Shares held
- 43.0M
- +583.0K (+1.4%) vs. Q1 2024
- Total value
- $808.6M
- −$171.9M (−17.5%) vs. Q1 2024
- New holders
- 5
- 10 more added
- Sold out
- 4
- 9 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PHVS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 125 | $2.23B |
| Q1 2026 | 110 | $1.67B |
| Q4 2025 | 106 | $1.64B |
| Q3 2025 | 83 | $1.44B |
| Q2 2025 | 60 | $792.7M |
| Q1 2025 | 52 | $705.5M |
| Q4 2024 | 54 | $855.8M |
| Q3 2024 | 51 | $834.2M |
| Q2 2024 | 36 | $808.6M |
| Q1 2024 | 35 | $980.5M |
| Q4 2023 | 36 | $1.14B |
| Q3 2023 | 21 | $606.6M |
| Q2 2023 | 21 | $441.6M |
| Q1 2023 | 21 | $173.9M |
| Q4 2022 | 25 | $239.6M |
| Q3 2022 | 21 | $173.6M |
| Q2 2022 | 20 | $494.0M |
| Q1 2022 | 22 | $397.1M |
| Q4 2021 | 22 | $321.1M |
| Q3 2021 | 25 | $380.3M |
| Q2 2021 | 28 | $406.3M |
| Q1 2021 | 33 | $616.5M |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Pharvaris N.V.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| UBS Group AG | 167 | $3.14K | 0.00% | +167 | New |
| Wells Fargo & Company | 700 | $13.2K | 0.00% | +700 | New |
| ADAR1 Capital Management, LLC | 2,000 | $37.6K | 0.01% | 00.0% | Unchanged |
| BlackRock Inc. | 2,268 | $42.6K | 0.00% | 00.0% | Unchanged |
| Virtus ETF Advisers LLC | 5,001 | $94.0K | 0.05% | +5,001 | New |
| Bank of America Corp | 6,121 | $115.1K | 0.00% | −1,687−21.6% | Reduced |
| Citadel Advisors LLC | 14,472 | $272.1K | 0.00% | −223,833−93.9% | Reduced |
| Y-Intercept (Hong Kong) Ltd | 15,883 | $298.6K | 0.02% | +15,883 | New |
| HighVista Strategies LLC | 16,750 | $314.9K | 0.12% | 00.0% | Unchanged |
| Morgan Stanley | 23,296 | $438.0K | 0.00% | −5,745−19.8% | Reduced |
| Geode Capital Management, LLC | 31,224 | $587.0K | 0.00% | 00.0% | Unchanged |
| HealthInvest Partners AB | 34,328 | $645.4K | 0.39% | +34,328 | New |
| Millennium Management LLC | 38,945 | $732.2K | 0.00% | +18,418+89.7% | Added |
| Walleye Capital LLC | 48,768 | $916.8K | 0.01% | −48,414−49.8% | Reduced |
| Marshall Wace, LLP | 51,168 | $962.0K | 0.00% | −7,001−12.0% | Reduced |
| Manufacturers Life Insurance Company, The | 55,078 | $1.04M | 0.00% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 61,470 | $1.16M | 0.00% | +30,354+97.6% | Added |
| TD Asset Management Inc | 85,816 | $1.61M | 0.00% | −26,800−23.8% | Reduced |
| Soleus Capital Management, L.P. | 399,430 | $7.51M | 0.66% | −2,471−0.6% | Reduced |
| Sphera Funds Management Ltd. | 403,265 | $7.58M | 1.24% | +10,388+2.6% | Added |
| Price T Rowe Associates Inc | 585,271 | $11.0M | 0.00% | −172,644−22.8% | Reduced |
| Sofinnova Investments, Inc. | 601,534 | $11.3M | 0.71% | +16,862+2.9% | Added |
| Rock Springs Capital Management LP | 756,931 | $14.2M | 0.43% | +4,007+0.5% | Added |
| 5AM Venture Management, LLC | 797,600 | $15.0M | 3.35% | 00.0% | Unchanged |
| EcoR1 Capital, LLC | 900,000 | $16.9M | 0.52% | 00.0% | Unchanged |
| Deerfield Management Company, L.P. (Series C) | 1,397,279 | $26.3M | 0.44% | +335,687+31.6% | Added |
| Cormorant Asset Management, LP | 1,466,460 | $27.6M | 1.60% | −245,000−14.3% | Reduced |
| Novo Holdings A/S | 1,725,000 | $32.4M | 1.75% | +556,970+47.7% | Added |
| Commodore Capital LP | 1,810,175 | $34.0M | 2.32% | +85,175+4.9% | Added |
| Bain Capital Life Sciences Investors, LLC | 3,303,381 | $62.1M | 6.82% | 00.0% | Unchanged |
| VR Adviser, LLC | 3,395,606 | $63.8M | 4.07% | 00.0% | Unchanged |
| Viking Global Investors LPSuperinvestorViking Global Investors | 3,653,310 | $68.7M | 0.26% | 00.0% | Unchanged |
| venBio Partners LLC | 4,289,304 | $80.6M | 34.83% | 00.0% | Unchanged |
| Foresite Capital Management IV, LLC | 4,293,854 | $80.7M | 54.23% | +255,012+6.3% | Added |
| FMR LLC | 5,205,656 | $97.9M | 0.01% | +12,672+0.2% | Added |
| General Atlantic LLC | 7,531,252 | $141.6M | 4.45% | 00.0% | Unchanged |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −30,138−100.0% | Sold out |
| Hudson Bay Capital Management LP | 0 | $0 | 0.00% | −20,018−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −11,700−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −3,150−100.0% | Sold out |